FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789048832> ?p ?o ?g. }

• W2789048832 endingPage "189" @default.
• W2789048832 startingPage "177" @default.
• W2789048832 abstract "BackgroundCocaine use disorder (CUD) is a debilitating condition with no NICE-recommended medication or specific psychosocial interventions. In the United Kingdom (UK), general counselling (treatment-as-usual; TAU) is widely delivered, but has limited effectiveness. We tested the feasibility, safety and preliminary efficacy of a novel, adjunctive psychosocial intervention for CUD, called ‘memory-focused cognitive therapy’ (MFCT).MethodsWe did a two-arm, external pilot randomised controlled trial at a specialist community National Health Service addictions clinic in London, UK. 30 adults (≥18 years), voluntarily seeking treatment for CUD (enrolled ≥14 days; all with moderate-to-severe DSM5 CUD), were individually randomised (1:1) to a control group (ongoing TAU; 3 × 90 min CUD cognitive conceptualisation assessments; 2 × 30 min cocaine-related cue-induction procedures; and 3 × 30 min research follow-ups); or to an intervention group (ongoing TAU; 3 × 90 min cognitive conceptualisation assessments; 2 × 30 min cocaine-related cue-induction procedures; 5 × 120 min, one-to-one, MFCT sessions [in 1 week]; and 3 × 60 min research follow-ups and MFCT-relapse prevention).The primary outcome was the total percentage score on the frequency version of the Craving Experiences Questionnaire (CEQ-F) at 1-month follow-up after the intensive intervention week (clinical endpoint; recall period past 2 weeks; higher score indicating greater craving). Secondary outcomes at the 1-month follow-up were percentage days abstinent (PDA) from cocaine, and longest period (days) of continuous abstinence (LPA) in the prior 28 days.Outcomes were analysed as an unadjusted group mean difference (with Hedge's g effect size [ES]) and a 95% Confidence Interval [CI] for the primary outcome and a 90% CI for the secondary outcomes. Exploratory, multivariable linear (primary outcome) and Poisson regression models (secondary outcomes), with sex, age, months of regular cocaine use, baseline outcome score, and group estimated the effectiveness of the intervention. The trial is registered with the ISCRTN (ISRCTN16462783).FindingsBetween July 15, 2015, and November 27, 2016, 58 patients were assessed for eligibility and 30 participants were randomised (14 to the control group and 16 to the intervention). With outcome data collected for all participants at the endpoint, the intervention group mean CEQ-F score (14·77; SD 21·47) was lower than the control group mean (51·75; SD 22·72); ES -1·62; 95% CI -2·45 to −0·80.MFCT was associated with more cocaine abstinence in the intervention group (PDA 85·94; SD 18·96) than the control group (PDA 54·59; SD 30·29); ES 1·19; 90% CI 0·54 to 1·84. There was also greater maximum abstinence in the intervention group (LPA 15·69; SD 10·10) than the control group (6·00; SD 7·36); ES 1·06; 90% CI 0·41 to 1·70. Exploratory, confounder-adjusted regression models for this preliminary effect supported the treatment association for reduced craving experiences (CEQ-F Coef. -28·25; 95% CI -45·15 to −11·35); more abstinence (PDA Incidence Rate Ratio [IRR] 1·56; 95% CI 1·31 to 1·88); and greater maximum abstinence (LPA IRR 2·56; 95% CI 1·96 to 3·35), although relative weak unmeasured confounding could overturn these model-adjusted exposure-outcome associations.There were four serious adverse events (among three participants). None were judged related to study procedures or interventions.InterpretationIn this first external pilot randomised controlled trial of MFCT for CUD, we have shown that the intervention and control procedures and acceptable feasible and safe, and report preliminary evidence that MFCT is associated with reduced craving and increased abstinence. These findings support progression to a substantive trial.Funding SourceUK National Institute for Health Research, Biomedical Research Centre." @default.
• W2789048832 created "2018-03-06" @default.
• W2789048832 creator A5002663392 @default.
• W2789048832 creator A5030252017 @default.
• W2789048832 creator A5033742666 @default.
• W2789048832 creator A5034067504 @default.
• W2789048832 creator A5060812676 @default.
• W2789048832 creator A5065751201 @default.
• W2789048832 creator A5080872036 @default.
• W2789048832 creator A5089823530 @default.
• W2789048832 date "2018-03-01" @default.
• W2789048832 modified "2023-10-04" @default.
• W2789048832 title "Memory-Focused Cognitive Therapy for Cocaine Use Disorder: Theory, Procedures and Preliminary Evidence From an External Pilot Randomised Controlled Trial" @default.
• W2789048832 cites W1562803040 @default.
• W2789048832 cites W1709787218 @default.
• W2789048832 cites W1914646574 @default.
• W2789048832 cites W1963523021 @default.
• W2789048832 cites W1964952275 @default.
• W2789048832 cites W1969348782 @default.
• W2789048832 cites W1970885260 @default.
• W2789048832 cites W1972376853 @default.
• W2789048832 cites W1972724492 @default.
• W2789048832 cites W1979258816 @default.
• W2789048832 cites W1985342736 @default.
• W2789048832 cites W1985739085 @default.
• W2789048832 cites W1986376109 @default.
• W2789048832 cites W1987562848 @default.
• W2789048832 cites W1991174296 @default.
• W2789048832 cites W2012801579 @default.
• W2789048832 cites W2015795623 @default.
• W2789048832 cites W2017966418 @default.
• W2789048832 cites W2023804136 @default.
• W2789048832 cites W2024605725 @default.
• W2789048832 cites W2035068440 @default.
• W2789048832 cites W2047747458 @default.
• W2789048832 cites W2048382391 @default.
• W2789048832 cites W2052078810 @default.
• W2789048832 cites W2054749214 @default.
• W2789048832 cites W2059581185 @default.
• W2789048832 cites W2061939000 @default.
• W2789048832 cites W2066588874 @default.
• W2789048832 cites W2071196687 @default.
• W2789048832 cites W2074460102 @default.
• W2789048832 cites W2074644622 @default.
• W2789048832 cites W2077594514 @default.
• W2789048832 cites W2078543098 @default.
• W2789048832 cites W2078716429 @default.
• W2789048832 cites W2101457117 @default.
• W2789048832 cites W2102401333 @default.
• W2789048832 cites W2106862702 @default.
• W2789048832 cites W2107871836 @default.
• W2789048832 cites W2109565047 @default.
• W2789048832 cites W2120718153 @default.
• W2789048832 cites W2124288307 @default.
• W2789048832 cites W2125885438 @default.
• W2789048832 cites W2127046953 @default.
• W2789048832 cites W2131433388 @default.
• W2789048832 cites W2133033756 @default.
• W2789048832 cites W2155479778 @default.
• W2789048832 cites W2169220235 @default.
• W2789048832 cites W2170785634 @default.
• W2789048832 cites W2171234119 @default.
• W2789048832 cites W2236170483 @default.
• W2789048832 cites W2275050342 @default.
• W2789048832 cites W2472306680 @default.
• W2789048832 cites W2560402077 @default.
• W2789048832 cites W2598796960 @default.
• W2789048832 cites W2735301415 @default.
• W2789048832 cites W2765749636 @default.
• W2789048832 cites W3162993738 @default.
• W2789048832 cites W4229632460 @default.
• W2789048832 cites W4235464748 @default.
• W2789048832 cites W4242353954 @default.
• W2789048832 cites W4362203253 @default.
• W2789048832 cites W4377217328 @default.
• W2789048832 doi "https://doi.org/10.1016/j.ebiom.2018.01.039" @default.
• W2789048832 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5925454" @default.
• W2789048832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29478874" @default.
• W2789048832 hasPublicationYear "2018" @default.
• W2789048832 type Work @default.
• W2789048832 sameAs 2789048832 @default.
• W2789048832 citedByCount "12" @default.
• W2789048832 countsByYear W27890488322018 @default.
• W2789048832 countsByYear W27890488322019 @default.
• W2789048832 countsByYear W27890488322020 @default.
• W2789048832 countsByYear W27890488322021 @default.
• W2789048832 countsByYear W27890488322022 @default.
• W2789048832 crossrefType "journal-article" @default.
• W2789048832 hasAuthorship W2789048832A5002663392 @default.
• W2789048832 hasAuthorship W2789048832A5030252017 @default.
• W2789048832 hasAuthorship W2789048832A5033742666 @default.
• W2789048832 hasAuthorship W2789048832A5034067504 @default.
• W2789048832 hasAuthorship W2789048832A5060812676 @default.
• W2789048832 hasAuthorship W2789048832A5065751201 @default.
• W2789048832 hasAuthorship W2789048832A5080872036 @default.
• W2789048832 hasAuthorship W2789048832A5089823530 @default.
• W2789048832 hasBestOaLocation W27890488321 @default.
• W2789048832 hasConcept C118552586 @default.

• next